When addressing HBP in AIS, it is also crucial to analyze the influence of parameters such as drug class and time to treatment on clinical results. Our subgroup analyses have shown that no individual drug class (i.e., calcium channel blockers (CCB), angiotensin II receptor antagonists (ARA), ACE inhibitors, and beta-blockers (BB)) had a significant effect on mortality or dependency of AIS patients. This evidence concerns the gene ACE and androgen insensitivity syndrome.